DeltaMSI: artificial intelligence-based modeling of microsatellite instability scoring on next-generation sequencing data.
Koen SwaertsFranceska DedeurwaerdereDieter De SmetPeter De JaegerGeert Antoine MartensPublished in: BMC bioinformatics (2023)
DeltaMSI achieved higher robustness at equal diagnostic power (AUC = 0.950; 95% CI 0.910-0.975) as compared to mSINGS (AUC = 0.876; 95% CI 0.823-0.918). Its sensitivity of 90% at 100% specificity indicated its clinical potential for high-throughput MSI screening in all tumor types. Clinical Trial Number/IRB B1172020000040, Ethical Committee, AZ Delta General Hospital.
Keyphrases
- artificial intelligence
- big data
- high throughput
- clinical trial
- machine learning
- deep learning
- electronic health record
- healthcare
- copy number
- single cell
- study protocol
- open label
- phase ii
- human health
- decision making
- acute care
- risk assessment
- circulating tumor
- randomized controlled trial
- double blind
- adverse drug
- dna methylation
- genetic diversity
- gene expression
- drug induced
- genome wide
- circulating tumor cells